Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren

Aspirin (niedrig dosiert) – Forschungsarchiv – Seite 18 von 61 | SupStack

Aspirin (niedrig dosiert) – Forschungsarchiv

Studien 1801–1850 von 3952, neueste zuerst

Die 1000 neuesten Studien – mit Evidenz-Zusammenfassung, Filtern und Suche – stehen auf der Hauptseite. Dieses Archiv listet die übrigen, 50 pro Seite. Zurück zur Hauptseite

1801Meta-Analyse2010

Younis N, Williams S, Ammori B, Soran H · Expert Opin Pharmacother (2010)

Für dieses Zitat ist keine Zusammenfassung hinterlegt — öffne die Arbeit, um das Abstract zu lesen.

Aspirin (niedrig dosiert) – Forschungsarchiv

Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis.

Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.

SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of low-molecular-weight heparin and low-dose aspirin in women with recurrent miscarriage.

Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.

Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial.

[Impact of different proton pump inhibitors on the antiplatelet activity of clopidogrel in combination with aspirin for patients undergoing coronary stent implantation].

Hyperglycemia-induced platelet activation in type 2 diabetes is resistant to aspirin but not to a nitric oxide-donating agent.

Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial.

Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention.

Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.

Aspirin for the prevention of cardiovascular disease: systematic review.

Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy.

Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials).

A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial.

Randomized controlled trial of dual antiplatelet therapy in patients undergoing surgery for critical limb ischemia.

Warfarin or aspirin in embolism prevention in patients with mitral valvulopathy and atrial fibrillation.

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.

Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.

To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial.

Effect of maximum OTC doses of naproxen sodium or acetaminophen on low-dose aspirin inhibition of serum thromboxane B2.

Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors.

Systemic low-dose aspirin and clopidogrel independently attenuate reflex cutaneous vasodilation in middle-aged humans.

Aspirin in the secondary prevention of cardiovascular disease: an update of the APTC meta-analysis.

Effect of two doses of aspirin on thromboxane biosynthesis and platelet function in patients undergoing coronary surgery.

Effect of aspirin and NSAIDs on risk and survival from colorectal cancer.

Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study.

Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.

Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme.

[Effects of low-dose aspirin on primary prevention of cardiovascular events: a systematic review].

[Primary prevention of cardiovascular disease with aspirin: what do the guidelines say?].

Sex differences in the administration-time-dependent effects of low-dose aspirin on ambulatory blood pressure in hypertensive subjects.

[Investigation of the effects of low dose aspirin therapy on primary and secondary prevention of cardiovascular disease].

Parnaparin versus aspirin in the treatment of retinal vein occlusion. A randomized, double blind, controlled study.

Frequency of microemboli signal in stroke patients treated with low molecular weight heparin or aspirin.

Safety and feasibility of a novel intravitreal tamponade using a silicone oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study.

Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers.

Low dose acetylsalicylic acid and shedding of microparticles in vivo in humans.

Rationale, design, and baseline data of the Japanese Primary Prevention Project (JPPP)-a randomized, open-label, controlled trial of aspirin versus no aspirin in patients with multiple risk factors for vascular events.

Prevention with low-dose aspirin plus dipyridamole in patients with disabling stroke.

Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation.

Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial.

[Recurrent thromboses and hemorrhagic complications in patients with antiphospholipid syndrome during therapy with warfarin plus aspirin].

Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 Fatty acids and low-dose aspirin.

Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial.

Aspirin-associated iron loss as an anticancer mechanism.

Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial.

The effect of aspirin on endothelial progenitor cell biology: preliminary investigation of novel properties.

Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial.

Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting.

[Acetylsalicylic acid in the primary and secondary prevention of vascular disease].